Latest News

  • 22nd October 2021

    Arecor commentary in MedNous on how faster insulin can enable the artificial pancreas

  • 11th October 2021

    ARECOR’S POLYSACCHARIDE VACCINE PATENT UPHELD

  • 20th September 2021

    ARECOR ANNOUNCES POSITIVE HEADLINE RESULTS FROM FIRST PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN CANDIDATE FOR DIABETES

News

Reset
  • 22/10/2021

    Arecor commentary in MedNous on how faster insulin can enable the artificial pancreas

  • 11/10/2021

    ARECOR’S POLYSACCHARIDE VACCINE PATENT UPHELD

  • 20/09/2021

    ARECOR ANNOUNCES POSITIVE HEADLINE RESULTS FROM FIRST PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN CANDIDATE FOR DIABETES

  • 09/09/2021

    FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR AT247, AN ULTRA-RAPID INSULIN FOR THE TREATMENT OF DIABETES

  • 07/09/2021

    EXCLUSIVE FORMULATION COLLABORATION WITH INTAS PHARMACEUTICALS LTD

  • 22/06/2021

    ARECOR TO PRESENT AT BIOTRINITY 2021

  • 10/06/2021

    Arecor appoints Dr Lindsey Foulkes as Chief Operating Officer

  • 07/06/2021

    ARECOR ANNOUNCES EXCLUSIVE FORMULATION STUDY COLLABORATION WITH PAR

  • 20/05/2021

    ARECOR ANNOUNCES AN EXCLUSIVE FORMULATION STUDY COLLABORATION WITH LILLY

  • 13/05/2021

    ARECOR GRANTED KEY US PATENT

  • 31/03/2021

    ARECOR RECEIVES £2.8 MILLION GRANT AWARD FROM INNOVATE UK